p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma

p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2014-01, Vol.2014 (2014), p.1-9
Main Authors: Teoh, P. J., Chng, Wee Joo
Format: Article
Language:English
Subjects:
Abnormalities
Apoptosis
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Cancer
Cancer therapies
Care and treatment
Cell cycle
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Colleges & universities
Drug Resistance, Neoplasm
Genes
Genomes
Health aspects
Humans
Medical prognosis
Membrane Proteins - genetics
Membrane Proteins - metabolism
Multiple myeloma
Multiple Myeloma - genetics
Multiple Myeloma - metabolism
Multiple Myeloma - therapy
Mutation
Nerve Tissue Proteins - genetics
Nerve Tissue Proteins - metabolism
Proteins
Proto-oncogenes
Review
Risk factors
Rodents
Tumor proteins
Tumor Suppressor Protein p53 - genetics
Tumor Suppressor Protein p53 - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:p53 abnormalities are regarded as an independent prognostic marker in multiple myeloma. Patients harbouring this genetic anomaly are commonly resistant to standard therapy. Thus, various p53 reactivating agents have been developed in order to restore its tumour suppressive abilities. Small molecular compounds, especially, have gained popularity in its efficacy against myeloma cells. For instance, promising preclinical results have steered both nutlin-3 and PRIMA-1 into phase I/II clinical trials. This review summarizes different modes of p53 inactivation in myeloma and highlights the current p53-based therapies that are being utilized in the clinic. Finally, we discuss the potential and promise that the novel small molecules possess for clinical application in improving the treatment outcome of myeloma.
ISSN:2314-6133
2314-6141
DOI:10.1155/2014/717919